Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969420 · ClinicalTrials.gov registry record · Phase 2
Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy
A Phase 2 study, sponsored by Sumitomo Pharma America.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT03969420 is a Phase 2 study that was terminated before completion, run by Sumitomo Pharma America. The registered enrollment target is 11 participants.
The verdict
NCT03969420, a Phase 2 study, was terminated before completion, sponsored by Sumitomo Pharma America.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.
Interventions
- DRUG Alvocidib (flavopiridol) and cytarabine (Ara-C)
- DRUG Alvocidib (flavopiridol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2021-05-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03969420
The ClinicalTrials.gov registry entry for NCT03969420 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alvocidib (flavopiridol) and cytarabine (Ara-C) is the first listed.
NCT03969420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03969420 about?
NCT03969420 is a clinical study titled "Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy". This study will evaluate the safety and efficacy of alvocidib in patients with AML who have either relapsed from or are refractory to venetoclax in combination with azacytidine or decitabine.
What is the current status of trial NCT03969420?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2020-01-15. Estimated completion is 2021-05-14.
What interventions are being tested in trial NCT03969420?
The interventions under investigation include: Alvocidib (flavopiridol) and cytarabine (Ara-C) (DRUG), Alvocidib (flavopiridol) (DRUG).
Who is sponsoring clinical trial NCT03969420?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.